Microbot Medical® to Commercially Debut the LIBERTY® System at The Symposium on Clinical Interventional Oncology Annual Meeting

Core Insights - Microbot Medical Inc. is set to exhibit its LIBERTY Endovascular Robotic System at the upcoming Symposium on Clinical Interventional Oncology, marking its first commercial presence post-FDA clearance [1][2] - The company has completed the recruitment of its commercial leadership team in preparation for the limited market launch of the LIBERTY System, expected in Q4 of this year [2][6] Company Developments - The LIBERTY System will be showcased at booth 208, where interventional oncologists can schedule live hands-on demonstrations [2] - Justin Bourne has joined as Regional Sales Director, bringing 20 years of experience in sales leadership within the healthcare industry, previously at Boston Scientific [3] - Dani Kulp has been appointed as Sales Training Director, with over 15 years of experience in medical education and sales training, focusing on endovascular therapies [4] - Xiomara Ortiz has taken on the role of Marketing Communications Manager, leveraging her extensive experience in digital marketing and brand strategy to enhance the company's brand presence [5] Strategic Outlook - The company has secured a logistics partner and is preparing for the limited market launch of the LIBERTY System, indicating strong momentum since receiving FDA clearance [6] - The addition of key commercial team members is aimed at building a solid foundation for both immediate launch plans and long-term commercial strategy [6] Company Background - Microbot Medical Inc. focuses on transforming endovascular procedures through advanced robotic technology, with the LIBERTY System being the first single-use, remotely operated robotic solution designed for precision and safety [7]